Revolutionizing the Way the Body Responds to Injury
Xequel’s aCT1 technology platform is designed to stimulate healing by creating an improved injury response. In healthy tissue, cells communicate with each other through gap junctions. In injured tissues, disrupted gap junctions can release signals outside of the cells. This signaling can have detrimental effects including inflammation and delayed or incomplete healing. Our proprietary aCT1 technology restores the gap junctions to normalize cell-to-cell signaling and facilitate healing.
0
Patents Obtained
$
0
M+
Research Funding(NIH/DOD)
0
Publications
0
+
Patients Servedin 9 clinical trials
0
%
Retention for 2021-22
Clinical Trials
Clinical Trials
0
+
Preclinical Studies
aCT1 is designed to impact healing by:
Accelerating the healing process
Reducing harmful
inflammation
Offering complete restoration
Providing safety and comfortable treatment
